Create a free account to get full platform access, discounts on medical reviews, newsletter insights from Dr. Busti, and more. No noise. Just value.
Discover and bookmark various collections and playlists
Free downloads - handouts, study material, show notes, etc.
Invited access to live-streamed events and Q&As with Dr. Busti
Submit your clinical questions for consideration for future episodes
Learn more about membership from Dr. Busti directly.
Already have an account? Log In
About
Library
Categories
Playlists
Collections
Live Events
Shop
Donate
Learn
Log In
My Content
My Account
Become a Member
Browse
Go Back
Save
Show
Hide
Filters
Reset
Primary Category
Healthcare Setting
Profession
Medical Specialty
Organ System
Disease State
Drug Category
Drug Class
Exam
alpha glucosidase inhibitors, alpha-glucosidase inhibitors, acarbose, miglitol, diabetes pharmacology, type 2 diabetes medications, intestinal alpha glucosidase, mechanism of action diabetes, busti, dr busti, anthony busti
pramlintide, amylin analog, amylin analogs, symlin, symlinpen, diabetes pharmacology, diabetes medications, antidiabetic drugs, insulin adjunct, adjunct to insulin, type 1 diabetes, type 2 diabetes, postprandial glucose, hypoglycemia risk, busti, dr busti
metformin, type 2 diabetes, metformin mechanism of action, metformin pharmacology, biguanide, biguanides, diabetes pharmacology, antidiabetic drugs, oral hypoglycemics, glucose lowering medications, metformin side effects, metformin lactic acidosis, metformin contraindications, metformin dosing, metformin renal dosing, dr busti
dpp4inhibitors, type2diabetes, sitagliptin, diabetes pharmacology, dpp4 inhibitor pharmacology, diabetes medications, incretin based therapy, glucosecontrol, type 2 diabetes treatment, linagliptin, saxagliptin, busti, dr busti
tirzepatide, mounjaro, zepbound, gip glp-1 agonist, dual incretin, glp-1 receptor agonist, gip agonist, type 2 diabetes, diabetes pharmacology, incretin mimetics, antidiabetic drugs, weight loss medication, obesity pharmacotherapy, busti, dr busti
glp 1 receptor agonist, glp1 agonists, semaglutide, ozempic, wegovy, rybelsus, liraglutide, victoza, saxenda, dulaglutide, trulicity, exenatide, byetta, bydureon, diabetes pharmacology, type 2 diabetes medications, incretin mimetics, weight loss medications, glucose lowering drugs, anthony busti, dr busti
insulin pharmacology, insulin types, rapid acting insulin, short acting insulin, intermediate acting insulin, NPH insulin, long acting insulin, basal insulin, bolus insulin, basal bolus regimen, mealtime insulin, insulin dosing, type 1 diabetes insulin, type 2 diabetes insulin, diabetes medications, busti, anthony busti, dr busti
meglitinides, repaglinide, nateglinide, type 2 diabetes, diabetes pharmacology, insulin secretagogues, repaglinide pharmacology, nateglinide pharmacology, busti, dr busti, Anthony Busti
sglt2 inhibitors, bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, jardiance, type2diabetes, diabetes pharmacology, antidiabetic drugs, diabetes medications, sglt2 mechanism, diabetes treatment, pharmacology made easy, busti, dr busti, anthony busti
sulfonylureas, glipizide, glyburide, glimepiride, type 2 diabetes, t2d pharmacology, diabetes medications, antidiabetic drugs, diabetes pharmacology, pharmacology lecture, step 1 pharmacology, mechanism of action sulfonylureas, second generation sulfonylureas, busti, dr busti, anthony busti
pioglitazone, tzd, thiazolidinediones, par gamma agonist, insulin sensitizer, type 2 diabetes, diabetes pharmacology, antidiabetic drugs, oral diabetes meds, glucose control, a1c reduction, pioglitazone side effects, heart failurer isk, rosiglitazone, busti, dr busti, anthony busti
